Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer

Carmine D'Aniello, Massimiliano Berretta, Carla Cavaliere, Sabrina Rossetti, Bianca Arianna Facchini, Gelsomina Iovane, Giovanna Mollo, Mariagrazia Capasso, Chiara Della Pepa, Laura Pesce, Davide D'Errico, Carlo Buonerba, Giuseppe Di Lorenzo, Salvatore Pisconti, Ferdinando De Vita, Gaetano Facchini

Research output: Contribution to journalReview article

Abstract

In the last decades, the prognosis of metastatic renal cell carcinoma (mRCC) has remarkably improved following the advent of the “targeted therapy” era. The expanding knowledge on the prominent role played by angiogenesis in RCC pathogenesis has led to approval of multiple anti-angiogenic agents such as sunitinib, pazopanib, axitinib, cabozantinib, sorafenib, and bevacizumab. These agents can induce radiological responses and delay cancer progression for months or years before onset of resistance, with a clinically meaningful activity. The need for markers of prognosis and efficacy of anti-angiogenic agents has become more compelling as novel systemic immunotherapy agents have also been approved in RCC and can be administered as an alternative to angiogenesis inhibitors. Anti PD-1 monoclonal antibody nivolumab has been approved in the second-line setting after tyrosine kinase inhibitors failure, while combination of nivolumab plus anti CTLA-4 monoclonal antibody ipilimumab has been approved as first-line therapy of RCC patients at intermediate or poor prognosis. In this review article, biomarkers of prognosis and efficacy of antiangiogenic therapies are summarized with a focus on those that have the potential to affect treatment decision-making in RCC. Biomarkers predictive of toxicity of anti-angiogenic agents have also been discussed.

Original languageEnglish
Article number1400
JournalFrontiers in Oncology
Volume9
DOIs
Publication statusPublished - Dec 11 2019

Keywords

  • angiogenesis
  • biomarkers
  • immunotherapy
  • prognosis
  • renal cell carcinoma
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer. / D'Aniello, Carmine; Berretta, Massimiliano; Cavaliere, Carla; Rossetti, Sabrina; Facchini, Bianca Arianna; Iovane, Gelsomina; Mollo, Giovanna; Capasso, Mariagrazia; Pepa, Chiara Della; Pesce, Laura; D'Errico, Davide; Buonerba, Carlo; Di Lorenzo, Giuseppe; Pisconti, Salvatore; De Vita, Ferdinando; Facchini, Gaetano.

In: Frontiers in Oncology, Vol. 9, 1400, 11.12.2019.

Research output: Contribution to journalReview article

D'Aniello, C, Berretta, M, Cavaliere, C, Rossetti, S, Facchini, BA, Iovane, G, Mollo, G, Capasso, M, Pepa, CD, Pesce, L, D'Errico, D, Buonerba, C, Di Lorenzo, G, Pisconti, S, De Vita, F & Facchini, G 2019, 'Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer', Frontiers in Oncology, vol. 9, 1400. https://doi.org/10.3389/fonc.2019.01400
D'Aniello, Carmine ; Berretta, Massimiliano ; Cavaliere, Carla ; Rossetti, Sabrina ; Facchini, Bianca Arianna ; Iovane, Gelsomina ; Mollo, Giovanna ; Capasso, Mariagrazia ; Pepa, Chiara Della ; Pesce, Laura ; D'Errico, Davide ; Buonerba, Carlo ; Di Lorenzo, Giuseppe ; Pisconti, Salvatore ; De Vita, Ferdinando ; Facchini, Gaetano. / Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer. In: Frontiers in Oncology. 2019 ; Vol. 9.
@article{dfa38d71da8c46d59c9dab9687671059,
title = "Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer",
abstract = "In the last decades, the prognosis of metastatic renal cell carcinoma (mRCC) has remarkably improved following the advent of the “targeted therapy” era. The expanding knowledge on the prominent role played by angiogenesis in RCC pathogenesis has led to approval of multiple anti-angiogenic agents such as sunitinib, pazopanib, axitinib, cabozantinib, sorafenib, and bevacizumab. These agents can induce radiological responses and delay cancer progression for months or years before onset of resistance, with a clinically meaningful activity. The need for markers of prognosis and efficacy of anti-angiogenic agents has become more compelling as novel systemic immunotherapy agents have also been approved in RCC and can be administered as an alternative to angiogenesis inhibitors. Anti PD-1 monoclonal antibody nivolumab has been approved in the second-line setting after tyrosine kinase inhibitors failure, while combination of nivolumab plus anti CTLA-4 monoclonal antibody ipilimumab has been approved as first-line therapy of RCC patients at intermediate or poor prognosis. In this review article, biomarkers of prognosis and efficacy of antiangiogenic therapies are summarized with a focus on those that have the potential to affect treatment decision-making in RCC. Biomarkers predictive of toxicity of anti-angiogenic agents have also been discussed.",
keywords = "angiogenesis, biomarkers, immunotherapy, prognosis, renal cell carcinoma, targeted therapy",
author = "Carmine D'Aniello and Massimiliano Berretta and Carla Cavaliere and Sabrina Rossetti and Facchini, {Bianca Arianna} and Gelsomina Iovane and Giovanna Mollo and Mariagrazia Capasso and Pepa, {Chiara Della} and Laura Pesce and Davide D'Errico and Carlo Buonerba and {Di Lorenzo}, Giuseppe and Salvatore Pisconti and {De Vita}, Ferdinando and Gaetano Facchini",
year = "2019",
month = "12",
day = "11",
doi = "10.3389/fonc.2019.01400",
language = "English",
volume = "9",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer

AU - D'Aniello, Carmine

AU - Berretta, Massimiliano

AU - Cavaliere, Carla

AU - Rossetti, Sabrina

AU - Facchini, Bianca Arianna

AU - Iovane, Gelsomina

AU - Mollo, Giovanna

AU - Capasso, Mariagrazia

AU - Pepa, Chiara Della

AU - Pesce, Laura

AU - D'Errico, Davide

AU - Buonerba, Carlo

AU - Di Lorenzo, Giuseppe

AU - Pisconti, Salvatore

AU - De Vita, Ferdinando

AU - Facchini, Gaetano

PY - 2019/12/11

Y1 - 2019/12/11

N2 - In the last decades, the prognosis of metastatic renal cell carcinoma (mRCC) has remarkably improved following the advent of the “targeted therapy” era. The expanding knowledge on the prominent role played by angiogenesis in RCC pathogenesis has led to approval of multiple anti-angiogenic agents such as sunitinib, pazopanib, axitinib, cabozantinib, sorafenib, and bevacizumab. These agents can induce radiological responses and delay cancer progression for months or years before onset of resistance, with a clinically meaningful activity. The need for markers of prognosis and efficacy of anti-angiogenic agents has become more compelling as novel systemic immunotherapy agents have also been approved in RCC and can be administered as an alternative to angiogenesis inhibitors. Anti PD-1 monoclonal antibody nivolumab has been approved in the second-line setting after tyrosine kinase inhibitors failure, while combination of nivolumab plus anti CTLA-4 monoclonal antibody ipilimumab has been approved as first-line therapy of RCC patients at intermediate or poor prognosis. In this review article, biomarkers of prognosis and efficacy of antiangiogenic therapies are summarized with a focus on those that have the potential to affect treatment decision-making in RCC. Biomarkers predictive of toxicity of anti-angiogenic agents have also been discussed.

AB - In the last decades, the prognosis of metastatic renal cell carcinoma (mRCC) has remarkably improved following the advent of the “targeted therapy” era. The expanding knowledge on the prominent role played by angiogenesis in RCC pathogenesis has led to approval of multiple anti-angiogenic agents such as sunitinib, pazopanib, axitinib, cabozantinib, sorafenib, and bevacizumab. These agents can induce radiological responses and delay cancer progression for months or years before onset of resistance, with a clinically meaningful activity. The need for markers of prognosis and efficacy of anti-angiogenic agents has become more compelling as novel systemic immunotherapy agents have also been approved in RCC and can be administered as an alternative to angiogenesis inhibitors. Anti PD-1 monoclonal antibody nivolumab has been approved in the second-line setting after tyrosine kinase inhibitors failure, while combination of nivolumab plus anti CTLA-4 monoclonal antibody ipilimumab has been approved as first-line therapy of RCC patients at intermediate or poor prognosis. In this review article, biomarkers of prognosis and efficacy of antiangiogenic therapies are summarized with a focus on those that have the potential to affect treatment decision-making in RCC. Biomarkers predictive of toxicity of anti-angiogenic agents have also been discussed.

KW - angiogenesis

KW - biomarkers

KW - immunotherapy

KW - prognosis

KW - renal cell carcinoma

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85077334433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077334433&partnerID=8YFLogxK

U2 - 10.3389/fonc.2019.01400

DO - 10.3389/fonc.2019.01400

M3 - Review article

AN - SCOPUS:85077334433

VL - 9

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - 1400

ER -